189 related articles for article (PubMed ID: 28469732)
1. The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.
Cohen SA; Yu M; Baker K; Redman M; Wu C; Heinzerling TJ; Wirtz RM; Charalambous E; Pentheroudakis G; Kotoula V; Kalogeras KT; Fountzilas G; Grady WM
Clin Epigenetics; 2017; 9():46. PubMed ID: 28469732
[TBL] [Abstract][Full Text] [Related]
2. Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability.
Flatin BTB; Vedeld HM; Pinto R; Langerud J; Lind GE; Lothe RA; Sveen A; Jeanmougin M
Int J Cancer; 2021 Apr; 148(7):1652-1657. PubMed ID: 33284993
[TBL] [Abstract][Full Text] [Related]
3. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.
Kawasaki T; Ohnishi M; Nosho K; Suemoto Y; Kirkner GJ; Meyerhardt JA; Fuchs CS; Ogino S
Mod Pathol; 2008 Mar; 21(3):245-55. PubMed ID: 18204436
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
Ogino S; Kawasaki T; Kirkner GJ; Kraft P; Loda M; Fuchs CS
J Mol Diagn; 2007 Jul; 9(3):305-14. PubMed ID: 17591929
[TBL] [Abstract][Full Text] [Related]
5. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
6. B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP).
Schernhammer ES; Giovannucci E; Baba Y; Fuchs CS; Ogino S
PLoS One; 2011; 6(6):e21102. PubMed ID: 21738611
[TBL] [Abstract][Full Text] [Related]
7. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
[TBL] [Abstract][Full Text] [Related]
8. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
[TBL] [Abstract][Full Text] [Related]
9. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
11. Cimp-Positive Status is More Representative in Multiple Colorectal Cancers than in Unique Primary Colorectal Cancers.
Tapial S; Olmedillas-López S; Rueda D; Arriba M; García JL; Vivas A; Pérez J; Pena-Couso L; Olivera R; Rodríguez Y; García-Arranz M; García-Olmo D; González-Sarmiento R; Urioste M; Goel A; Perea J
Sci Rep; 2019 Jul; 9(1):10516. PubMed ID: 31324877
[TBL] [Abstract][Full Text] [Related]
12. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
[TBL] [Abstract][Full Text] [Related]
13. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
14. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
[TBL] [Abstract][Full Text] [Related]
15. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.
Cha Y; Kim KJ; Han SW; Rhee YY; Bae JM; Wen X; Cho NY; Lee DW; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Kang GH; Kim TY
Br J Cancer; 2016 Jul; 115(2):164-71. PubMed ID: 27310704
[TBL] [Abstract][Full Text] [Related]
16. The role of the CpG island methylator phenotype on survival outcome in colon cancer.
Kang KJ; Min BH; Ryu KJ; Kim KM; Chang DK; Kim JJ; Rhee JC; Kim YH
Gut Liver; 2015 Mar; 9(2):202-7. PubMed ID: 25167802
[TBL] [Abstract][Full Text] [Related]
17. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
[TBL] [Abstract][Full Text] [Related]
18. Stage III colorectal cancer: molecular disparity between primary cancers and lymph node metastases.
Messick CA; Church JM; Liu X; Ting AH; Kalady MF
Ann Surg Oncol; 2010 Feb; 17(2):425-31. PubMed ID: 19885699
[TBL] [Abstract][Full Text] [Related]
19. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
[TBL] [Abstract][Full Text] [Related]
20. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Ogino S; Meyerhardt JA; Kawasaki T; Clark JW; Ryan DP; Kulke MH; Enzinger PC; Wolpin BM; Loda M; Fuchs CS
Virchows Arch; 2007 May; 450(5):529-37. PubMed ID: 17372756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
